PureTech Health

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

Retrieved on: 
星期二, 五月 7, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Risk, Daphne, Innovation, Neuropsychiatry, Culture, Biomarker, Genzyme, Synageva, Sleep, Karuna, Yale University, Harvard Medical School, PRTC, Bristol Myers Squibb, Therapy, Alnylam Pharmaceuticals, Management, DSM-IV codes, Johnson & Johnson, Eli Lilly, Neuroscience, Depression, University of Michigan, Chemical engineering, Multimedia, Anxiety, Organization, Stanford University, University, PureTech Health, RNA interference, Lymphatic system, P&L, Patient, Acquisition, Pleasure, MBA, Growth

View the full release here: https://www.businesswire.com/news/home/20240507753971/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240507753971/en/
    PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments (Graphic: Business Wire)
    The appointments follow the recent launch of Seaport , PureTech’s newest Founded Entity, with a $100 million Series A financing round.
  • Following the Series A financing, PureTech holds equity ownership in Seaport of 61.5 percent on a diluted basis.
  • In addition, Michael Chen, Ph.D., Co-founder, was named Chief Scientific Officer, and Eric Green, MBA, was appointed Chief Operating Officer.
  • The appointments follow the recent launch of Seaport with a $100 million Series A financing round to advance the development of novel neuropsychiatric medicines.

Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

Retrieved on: 
星期二, 五月 7, 2024
Health, Pharmaceutical, Risk, Daphne, Innovation, Neuropsychiatry, Culture, Biomarker, Genzyme, Synageva, Sleep, Karuna, Yale University, Harvard Medical School, Bristol Myers Squibb, Therapy, Alnylam Pharmaceuticals, Management, DSM-IV codes, Johnson & Johnson, Eli Lilly, Neuroscience, Depression, University of Michigan, Chemical engineering, Anxiety, Organization, Stanford University, University, PureTech Health, RNA interference, Lymphatic system, P&L, Science, Patient, Acquisition, Pleasure, MBA, Growth

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the appointment of Denice Torres, J.D., to its Board of Directors.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the appointment of Denice Torres, J.D., to its Board of Directors.
  • The appointments follow the recent launch of Seaport with a $100 million Series A financing round to advance the development of novel neuropsychiatric medicines.
  • “We are incredibly honored to welcome Denice to our Board of Directors.
  • She is an exceptional healthcare leader with a track record of successfully guiding organizations through significant growth and transformation,” said Steve Paul, M.D., Founder and Chair of the Board of Directors at Seaport.

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
星期二, 四月 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
星期二, 四月 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Retrieved on: 
星期二, 二月 27, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Bangladesh Technical Education Board, Takeda Pharmaceutical Company, MPM, Schering-Plough, Science Publishing Group, Hoechst AG, Research and development, NIH, Moderna, PureTech Health, Drug development, Bristol Myers Squibb, Doctor of Philosophy, Renegade, University, Partner, RNA, Therapy, Patient, Protein, Takeda Oncology, Development, Immune system, Pharmaceutical industry

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
  • “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
  • Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
  • Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.

Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region - ResearchAndMarkets.com

Retrieved on: 
星期四, 二月 8, 2024
Pharmaceutical, Health, Mental Health, Internet, Anxiety, DSM-IV codes, SAD, MDD, Research, PureTech Health, USD, Pharmacy, Social anxiety disorder, Prevalence, Patient, Distribution, GAD, PH94B, Ulotaront, FDA, Disorder, Tic disorder, PPD, Market, Depression, AbbVie, Zuranolone, MOA, Food, Commercialization, Therapy, TAAR1, Major depressive disorder, Sunovion, ADAA, Postpartum depression, NDA, Biogen, Conference, Pharmaceutical industry

The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.
  • The global anxiety disorders and depression treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Rising research & development activities for the development of innovative drugs for the treatment of anxiety & depression disorders is predicted to boost the market growth during the forecast period.
  • This application pertains to the use of cariprazine as an add-on treatment for individuals with major depressive disorder (MDD) who are already undergoing antidepressant therapy.

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Retrieved on: 
星期四, 十二月 7, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, UCLA, Neck, The, Tislelizumab, Apoptosis, BeiGene, Head, Colorectal cancer, Acute myeloid leukemia, PureTech Health, Carcinoma, Mortality, ESMO, Patient, LSE, PRTC, Bone marrow, Pharmaceutical industry, Medicine

LYT-200 is an anti-galectin-9 antibody being evaluated as a monotherapy and in combination with tislelizumab, an anti-PD-1 antibody developed by BeiGene, in metastatic solid tumors, including urothelial and head and neck cancers.

Key Points: 
  • LYT-200 is an anti-galectin-9 antibody being evaluated as a monotherapy and in combination with tislelizumab, an anti-PD-1 antibody developed by BeiGene, in metastatic solid tumors, including urothelial and head and neck cancers.
  • LYT-200 is also in development for the treatment of hematological malignancies, such as acute myeloid leukemia.
  • The monotherapy arm of the trial has been completed, and the clinically relevant dose was selected for the Phase 2 portion of the trial.
  • The poster titled “Phase 1/2 Trial of Galectin-9 Antibody LYT-200 +/- Tislelizumab” will be presented today at The ESMO Immuno-Oncology Congress 2023, which is taking place in Geneva, Switzerland.

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

Retrieved on: 
星期三, 十一月 29, 2023
FDA, Pharmaceutical, Health, Mental Health, NDA, Neuropsychiatry, DSM-IV codes, KRTX, Safety, Employment, Food, Therapy, PureTech Health, Risk, PANSS, LSE, Nature, PRTC, Weight gain, New Drug Application, Master of Education, Housing, PDUFA, Psychiatry, Somnolence, Life, Pharmaceutical industry, Schizophrenia, KarXT

The application has been granted a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024.

Key Points: 
  • The application has been granted a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024.
  • The NDA submission is supported by efficacy and long-term safety data from the EMERGENT program, the clinical program evaluating KarXT as a treatment for schizophrenia.
  • PureTech is a founder of Karuna and co-inventor of the KarXT program.
  • If approved, KarXT will be the third therapeutic candidate to be taken from inception at PureTech to FDA regulatory approval.

PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Retrieved on: 
星期五, 十一月 17, 2023
Cardiology, Biotechnology, Pharmaceutical, General Health, Health, FDA, Mental Health, Clinical Trials, NDA, KRTX, Schizophrenia, Safety, Food, Therapy, PureTech Health, Assessment, LSE, BID, Heart rate, PRTC, New Drug Application, Diagnosis, Mercury (element), Psychiatry, Blood pressure, Pharmaceutical industry, KarXT

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Karuna Therapeutics (NASDAQ: KRTX), announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood pressure in adults with schizophrenia demonstrating that KarXT was not associated with increases in blood pressure.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Karuna Therapeutics (NASDAQ: KRTX), announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood pressure in adults with schizophrenia demonstrating that KarXT was not associated with increases in blood pressure.
  • The primary endpoint in the trial was the change from baseline at week 8 in 24-hour average ambulatory systolic blood pressure.
  • In the trial, KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg.
  • In the trial, KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg.

PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers

Retrieved on: 
星期二, 十一月 14, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, CNS, Allopregnanolone, Schizophrenia, Daphne, Trier social stress test, PureTech Health, Anxiety, Neurosteroid, Patient, Multimedia, LSE, KarXT, Alprazolam, PRTC, Psychiatry, FRCPC, Epilepsy, Pharmacology, Therapy, Benzodiazepine, Stress-related disorders, DSM-IV codes, MPH, University, TSST, Massachusetts General Hospital, Public health, Glyph, Central nervous system, Volunteering, Hospital, Pharmaceutical industry, MD

The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.

Key Points: 
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • View the full release here: https://www.businesswire.com/news/home/20231113556006/en/
    PureTech announced topline results from its Phase 2a, randomized, placebo-controlled, proof-of-concept trial of LYT-300 (oral allopregnanolone).
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • An increase in cortisol levels after the TSST is a physiological response and an objective biomarker of acute stress.